[Clinical practice guidelines of HAP/VAP in 2016: the updates]

Area of Science:

• Infectious Diseases
• Critical Care Medicine
• Clinical Practice Guidelines

Background:

• Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) are significant healthcare-associated infections.
• These infections lead to increased mortality, prolonged hospital stays, and higher healthcare costs.
• The Infectious Diseases Society of America (IDSA) and American Thoracic Society (ATS) updated guidelines in 2016.

Purpose of the Study:

• To critically evaluate the 2016 IDSA/ATS guidelines for HAP and VAP diagnosis and treatment.
• To identify recommendations based on low-quality evidence.
• To analyze discrepancies between guideline recommendations and current clinical practices in China.

Main Methods:

• Review of the 2016 IDSA/ATS guidelines.
• Critical appraisal of the evidence supporting guideline recommendations.
• Comparative analysis of guideline recommendations versus clinical implementation in China.

Main Results:

• Many recommendations in the 2016 guidelines are based on low or very-low quality evidence.
• Certain strong recommendations diverge from established clinical practices in China.
• Specific aspects of the guidelines require critical consideration for local application.

Conclusions:

• The 2016 HAP/VAP guidelines necessitate careful interpretation due to evidence limitations.
• Clinical application in China may require adaptation of certain recommendations.
• Further research and evidence are needed to refine HAP and VAP management strategies.